|

Tegafur Clinical Trials

5 actively recruiting trials

Also known as: S-1, tislelizumab

Pipeline

Phase 2: 5

Top Sponsors

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University2
  • Zekuan Xu1
  • The First Affiliated Hospital with Nanjing Medical University1
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1

Indications

  • Cancer5
  • Esophageal Squamous Cell Carcinoma2
  • Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma1
  • Esophagogastric Junction Adenocarcinoma1
  • Neoadjuvant Chemoimmunotherapy1

Other5 trials

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
Phase 2
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Phase 2
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
Phase 2
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.